Explore the words cloud of the BreathSpec project. It provides you a very rough idea of what is the project "BreathSpec" about.
The following table provides information about the project.
IMSPEX DIAGNOSTICS LIMITED
|Coordinator Country||United Kingdom [UK]|
|Total cost||3˙323˙172 €|
|EC max contribution||2˙367˙647 € (71%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2. (PRIORITY 'Industrial leadership')
|Duration (year-month-day)||from 2017-05-01 to 2019-07-31|
Take a look of project's partnership.
|1||IMSPEX DIAGNOSTICS LIMITED||UK (ABERCYNON)||coordinator||1˙141˙700.00|
|2||G.A.S. GESELLSCHAFT FUR ANALYTISCHESENSORSYSTEME M.B.H.||DE (DORTMUND)||participant||507˙150.00|
|3||STATISTICAMEDICA LIMITED||IE (DUBLIN)||participant||462˙087.00|
|4||THE UNIVERSITY OF WARWICK||UK (COVENTRY)||participant||140˙422.00|
|5||REDKNIGHT CONSULTANCY LTD||UK (PONTYCLUN)||participant||116˙287.00|
The world faces a growing epidemic of antimicrobial resistance (AMR); however, only two new classes of antibiotics have been brought to the market in the last 30 years. The discovery and development of new antibiotics is essential to maintain medical advances but poses significant scientific, clinical, and financial challenges, particularly for antibiotics active against Gram-negative bacteria (such as E. coli). Such bacteria have effective barriers against drugs, making treatment difficult, resistance likely and development costs and risks high. In addition, any new antibiotics brought to the market would likely be used cautiously to delay the development of resistance, adding an additional financial challenge in recouping the development costs. The O’Neill Report on AMR identifies diagnostics as critical to the battle against antibiotic resistance.
This innovation action, BreathSpec, proposes a viable solution to the global problem of AMR through the final developmental stages of an existing diagnostic device, which will allow a rapid, binary decision to be made on the need for antibiotic treatment, and which with suitable optimisation will allow further differentiation and stratification to take place. The Innovation Action includes technical developments to optimise its function, data acquisition for the development of the decision making analytical function and clinical validation.
It addresses these issues by producing reliable identification and quantification of key signature volatiles present in exhaled breath. It provides a non-invasive method for monitoring the volatile organic compounds present in an individual’s exhaled breath (and subsequently the blood) and has long been recognised as having significant utility as a clinical test that can be used for early disease detection and monitoring, and potentially to diagnose specific bacterial infections for better, more targeted use of existing antibiotics.
|Marketing material regarding project results/outcomes||Websites, patent fillings, videos etc.||2020-02-14 11:51:57|
|Promotional material||Websites, patent fillings, videos etc.||2020-02-14 11:51:57|
Take a look to the deliverables list in detail: detailed list of BreathSpec deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREATHSPEC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BREATHSPEC" are provided by the European Opendata Portal: CORDIS opendata.